[1] Yin WJ, Lu JS, Di GH, et al. Clinicopathologcal features of the triple-negative tumors in Chinese breast cancer patients[J]. Breast Cancer Res Treat, 2007, 109(1):25 -32.
[2] Reis-Filho JS, Futt AN. Triple negative tumours:a critical review[J]. Histopathol, 2008, 52(1):108 -118.
[3] Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breastcancer and obesity in a rural Appalachian population[J]. CancerEpidemiol Biomarkers Prev, 2008, 17(12):3319 -3324.
[4] Jang SM, Han H, Jang KS, et al. The glycolytic phenotype is correlated with aggressiveness and poor prognosis in invasive ductal carcinomas[J]. Breast Cancer, 2012, 15(2):172 -180.
[5] Di Bonito M, Cantile M, Collina F, et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer [J]. Breast Cancer, 2012, 15(2):162 -171.
[6] Bartsch R, Ziebermayr R, Christoph C, et al. Triple-negative breast cancer[J]. Wien Medwochenschr, 2010, 160 ( 7/8 ):174 -181.
[7] Hoadlcy KA, Weigman VJ, Fan C, et al. EGFB associated expression profiles vary with breast tumor subtype[J]. BMC Genom ics, 2007, 8:258.
[8] Garey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative( basal-like) breast cancer[J]. Clin Oncol, 2008, 26(15):1009.
[9] Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative ( triplenegative)breast cancer[J]. Anticancer Drugs, 2007, 18 (7):835 -837.
[10] Cheng X, Liu H, Fang L, et al. 2-DG enhances chemosensitivity of breast cancer cells to adriamycin[J]. Chin Pharmacol Bull, 2010, 26(10):1371 -1376.
[11] Liu H, Jiang CC, Lavis CJ, et al. 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2[J]. Mol Cancer, 2009, 14(8):122.
[12] Boopalan T, Arumugam A, Damodaran C, et al. The Anticancer effect of 2'-3'-dehydrosalannol on triple-negative breast cancer cells[J]. Anticancer Res, 2012, 32(7):2801 -2806.
[13] Zhao HM, Zhang B, Li Y, et al. Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells[J]. Zhonghua Zhong Liu Za Zhi, 2012, 34(2):84 -88.